Definium Therapeutics, Inc. Research and Development Expense
Definium Therapeutics, Inc. (DFTX) reported Research and Development Expense of $48.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Definium Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $48.66M, a 63.26% increase year-over-year.
- Definium Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $41.48M, a 77.61% increase year-over-year.
- Definium Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $33.52M, a 54.06% increase year-over-year.
- Definium Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $30.98M, a 80.23% increase year-over-year.
- Definium Therapeutics, Inc. research and development expense for fiscal 2025 was $117.67M, a 80.20% increase from fiscal 2024.
- Definium Therapeutics, Inc. research and development expense for fiscal 2024 was $65.30M, a 25.27% increase from fiscal 2023.
- Definium Therapeutics, Inc. research and development expense for fiscal 2023 was $52.12M, a 44.11% increase from fiscal 2022.
- Definium Therapeutics, Inc. research and development expense for fiscal 2022 was $36.17M, a 3.97% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 7 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $48.66M 10-Q · filed 2026-08-06 | $90.15M 10-Q · filed 2026-08-06 | $123.67M derived: sum of 3 quarters · filed 2026-08-06 | $154.65M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $41.48M 10-Q · filed 2026-05-07 | $75.00M derived: sum of 2 quarters · filed 2026-05-07 | $105.98M derived: sum of 3 quarters · filed 2026-05-07 | $135.79M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $33.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $64.50M derived: sum of 2 quarters · filed 2026-02-26 | $94.31M derived: sum of 3 quarters · filed 2026-08-06 | $117.67M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $30.98M 10-Q · filed 2025-11-06 | $60.79M derived: sum of 2 quarters · filed 2026-08-06 | $84.14M 10-Q · filed 2025-11-06 | $105.90M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $29.81M 10-Q · filed 2026-08-06 | $53.17M 10-Q · filed 2026-08-06 | $74.92M derived: sum of 3 quarters · filed 2026-08-06 | $92.11M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $23.36M 10-Q · filed 2026-05-07 | $45.12M derived: sum of 2 quarters · filed 2026-05-07 | $62.30M derived: sum of 3 quarters · filed 2026-05-07 | $76.95M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $21.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.95M derived: sum of 2 quarters · filed 2026-02-26 | $53.59M derived: sum of 3 quarters · filed 2026-02-26 | $65.30M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $17.19M 10-Q · filed 2025-11-06 | $31.83M derived: sum of 2 quarters · filed 2025-11-06 | $43.54M 10-Q · filed 2025-11-06 | $55.08M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $14.64M 10-Q · filed 2025-07-31 | $26.35M 10-Q · filed 2025-07-31 | $37.90M derived: sum of 3 quarters · filed 2025-07-31 | $51.10M derived: sum of 4 quarters · filed 2025-07-31 | |
| 2024-03-31 | $11.71M 10-Q · filed 2025-05-08 | $23.25M derived: sum of 2 quarters · filed 2025-05-08 | $36.45M derived: sum of 3 quarters · filed 2025-05-08 | $51.23M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $24.75M derived: sum of 2 quarters · filed 2025-03-06 | $39.53M derived: sum of 3 quarters · filed 2025-03-06 | $52.12M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $13.20M 10-Q · filed 2024-11-07 | $27.98M derived: sum of 2 quarters · filed 2024-11-07 | $40.58M 10-Q · filed 2024-11-07 | $49.41M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $14.78M 10-Q · filed 2024-08-13 | $27.38M 10-Q · filed 2024-08-13 | $36.21M derived: sum of 3 quarters · filed 2024-08-13 | $43.98M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $12.60M 10-Q · filed 2024-05-08 | $21.43M derived: sum of 2 quarters · filed 2024-05-08 | $29.20M derived: sum of 3 quarters · filed 2024-05-08 | $38.53M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $8.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $16.60M derived: sum of 2 quarters · filed 2024-02-28 | $25.93M derived: sum of 3 quarters · filed 2024-02-28 | $36.17M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $7.77M 10-Q · filed 2023-11-02 | $17.10M derived: sum of 2 quarters · filed 2023-11-02 | $27.34M 10-Q · filed 2023-11-02 | $38.22M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | $9.33M 10-Q · filed 2023-08-03 | $19.57M 10-Q · filed 2023-08-03 | $30.45M derived: sum of 3 quarters · filed 2023-08-03 | $39.47M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $10.24M 10-Q · filed 2023-05-04 | $21.12M derived: sum of 2 quarters · filed 2023-05-04 | $30.14M derived: sum of 3 quarters · filed 2023-05-04 | $38.22M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $19.90M derived: sum of 2 quarters · filed 2023-03-09 | $27.98M derived: sum of 3 quarters · filed 2023-03-09 | $34.79M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $9.02M 10-Q · filed 2022-11-10 | $17.09M derived: sum of 2 quarters · filed 2022-11-10 | $23.91M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $8.07M 10-Q · filed 2022-08-11 | $14.89M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $6.81M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $18.63M 10-K · filed 2022-03-28 | ||||
| 2019-12-31 | $7.55M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |